Loading quotes...
Forecast
The analysts' average price target is €148.85 (+3.51%). The median is €146.55 (+1.91%).
| Buy |
13 |
| Hold |
18 |
| Sell |
0 |
News Go to news feed
PerkinElmer pays 2025 dividend of $0.28; payout $32.80 million
PerkinElmer decided at the annual general meeting on a dividend for 2025 of $0.28 per share, unchanged from the previous year, totaling $32.80 million and representing a total payout down 4.79%. The dividend yield for 2025 is 0.29%; the share price in New York fell 10.01% over the year, and the total return including the dividend is -9.71%. FactSet also expects $0.28 for 2026 and estimates the dividend yield then at 0.33%. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | July 2026 | YoY |
|---|---|---|
| Revenue | 638M | 3.87% |
| Gross profit | 364.48M | 1.67% |
| Net profit | 45.31M | 1.51% |
| EBITDA | 164.87M | 0.10% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €12.92B |
Number of shares | 125.44M |
52-week high/low | €151.91 - €101.13 |
Dividend yield | 0.17% |
Dividends TTM | €0.24 |
Next dividend | €0.0624 |
Beta | 1.10 |
P/E ratio | 75.60 |
PEG ratio | -6.86 |
P/B ratio | 2.45 |
P/S ratio | 6.08 |
Company profile
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
| Name | Revvity |
| CEO | Prahlad R. Singh |
| Headquarters | Waltham,
ma USA |
| Website | |
| Sector | Information Technology |
| Industry | Technology Hardware, Storage & Peripherals |
| IPO | 07/06/1965 |
| Employees | 16,700 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | PKI |
Düsseldorf | PKN.DU |
Frankfurt | PKN.F |
London | 0KHE.L |
München | PKN.MU |
SIX | PKN.SW |
London Stock Exchange | 0KHE.L |
Tai | 2636.TW |
Ist | AYEN.IS |
Pnk | ZHSHF |
NYSE | RVTY |